RecruitingPhase 4NCT03384563

Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

Sponsor

Baylor College of Medicine

Enrollment

180 participants

Start Date

Feb 18, 2018

Study Type

INTERVENTIONAL

Conditions

Pediatric Anesthesia

Summary

The purpose of this protocol is to determine the effect of two clinically applicable Dexmedetomidine dosages (0.5mcg/kg and 1mcg/kg) on the minimum alveolar concentration (MAC) of Sevoflurane in children between the age ranges of: 1-6 months; 6-12 months of age and 12 months-36 months years of age.

Eligibility

Min Age: 1 MonthMax Age: 36 Months

Inclusion Criteria1

All patients age 1 month- 3 years presenting for surgery.

Exclusion Criteria14

Interstitial lung disease, chest wall disease, or bronchospastic disease with no flare-ups in the past 2 weeks of presentation
History of difficult intubation or ventilation
Airway malformation
Congenital heart disease
Cardiac arrhythmias
Central nervous system disease, including developmental delay, cerebral palsy, or seizure disorder
History of or family history of malignant hyperthermia
Electrolyte disorders
Gastrointestinal disease
Hepatic dysfunction
Renal dysfunction
Metabolic disease, such as diabetes
Obesity, defined as a body mass index greater than the 95% percentile for age
Preterm infant (less than 37 weeks gestational age) 15. Use of any medications (anticonvulsants, opioids, benzodiazepines, antibiotics, antihistamines drugs that induce hepatic enzymes) that may affect MAC.